Overview
Contraindications
When this intervention should not be used
Warnings and Precautions (5.5) Adverse Reactions (6.1) [seeand] The use of Infliximab at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure. Warnings and Precautions (5.7) Adverse Reactions (6.1) [seeand]. Infliximab is contraindicated in patients with a previous sev
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
Clinical Trials
84 trials linked to this intervention
Recent Trials
Immune Regulation in Ulcerative Colitis or Crohn s Disease
The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels
Asacol Dosing Study for Active Ulcerative Colitis
Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205)
Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Specialists
Providers who commonly manage this intervention
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Infliximab (substance)
- SNOMED CT
- 386891004
- UMLS CUI
- C0666743
- RxNorm CUI
- 191831
- Labeler
- Janssen Biotech, Inc.
Clinical Data
This intervention maps to 10 entities in the Ltrl knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.